Valentine Suteau1, Pierre-Jean Saulnier2, Matthieu Wargny3, Linda Gonder-Frederick4, Elise Gand5, Lucy Chaillous6, Ingrid Allix7, Séverine Dubois8, Fabrice Bonnet9, Anne-Marie Leguerrier10, Gerard Fradet11, Ingrid Delcourt Crespin12, Véronique Kerlan13, Didier Gouet14, Caroline Perlemoine15, Pierre-Henri Ducluzeau16, Matthieu Pichelin17, Stéphanie Ragot18, Samy Hadjadj19, Bertrand Cariou20, Claire Briet21. 1. Institut MITOVASC, UMR CNRS 6015, INSERM 1083, Université d'Angers, 3 rue Roger Amsler, 49100 Angers, France; Diabetes Department, CHU d'Angers, 4 rue Larrey, 49100 Angers, France. Electronic address: valentine.courant@chu-angers.fr. 2. Clinical Investigation Center CIC1402, CHU de Poitiers 2 rue de la Miletrie, 86000 Poitiers, France; CHU Poitiers, Diabetes Department, 2 rue de la Milétrie, CS 90577, 86000 Poitiers, France. Electronic address: pierrejean.saulnier@gmail.com. 3. L'institut du thorax, CHU Nantes, INSERM CIC1413, Hôpital Nord Laennec Boulevard Jacques-Monod Saint-Herblain, 44093 Nantes Cedex 1, France. Electronic address: matthieu.wargny@chu-nantes.fr. 4. University of Virginia, Charlottesville, VA, USA. Electronic address: LAG3G@hscmail.mcc.virginia.edu. 5. Clinical Investigation Center CIC1402, CHU de Poitiers 2 rue de la Miletrie, 86000 Poitiers, France. Electronic address: elise.gand@chu-poitiers.fr. 6. L'institut du thorax, CHU Nantes, INSERM CIC1413, Hôpital Nord Laennec Boulevard Jacques-Monod Saint-Herblain, 44093 Nantes Cedex 1, France. Electronic address: lucy.chaillous@chu-nantes.fr. 7. Diabetes Department, CHU d'Angers, 4 rue Larrey, 49100 Angers, France. Electronic address: In.Allix@chu-angers.fr. 8. Diabetes Department, CHU d'Angers, 4 rue Larrey, 49100 Angers, France; INSERM U1063, Oxidative Stress and Metabolic Pathologies, Université d'Angers, CHU Angers, 4 Rue Larrey, 49933 Angers Cedex 9, France. Electronic address: Se.Dubois@chu-angers.fr. 9. CHU Rennes, Diabetes Department, 2 rue Henri Le Guilloux, 35033 Rennes Cedex 9, France. Electronic address: fabrice.bonnet@chu-rennes.fr. 10. CHU Rennes, Diabetes Department, 2 rue Henri Le Guilloux, 35033 Rennes Cedex 9, France. 11. CH Départemental Vendée, Boulevard Stéphane Moreau, 85000 La Roche-sur-Yon, France. Electronic address: gerard.fradet@chd-vendee.fr. 12. CH Départemental Vendée, Boulevard Stéphane Moreau, 85000 La Roche-sur-Yon, France. Electronic address: ingrid.delcourt-crespin@chd-vendee.fr. 13. CHU Brest, Diabetes Department, Hôpital de La Cavale Blanche, Boulevard Tanguy Prigent, 29200 Brest, France. Electronic address: veronique.kerlan@chu-brest.fr. 14. CH La Rochelle, Diabetes Department, Rue du docteur Schweitzer, 17019 La Rochelle Cedex, France. Electronic address: didier.gouet@ch-larochelle.fr. 15. CH Bretagne Sud, Diabetes Department, 5 Avenue Choiseul, 56322 Lorient, France. Electronic address: c.perlemoine@ch-bretagne-sud.fr. 16. CHU Tours, Diabetes Department, 2, boulevard Tonnellé, 37044 Tours cedex 9, France. Electronic address: ph.ducluzeau@chu-tours.fr. 17. L'institut du thorax, CHU Nantes, INSERM CIC1413, Hôpital Nord Laennec Boulevard Jacques-Monod Saint-Herblain, 44093 Nantes Cedex 1, France. Electronic address: Matthieu.Pichelin@univ-nantes.fr. 18. Clinical Investigation Center CIC1402, CHU de Poitiers 2 rue de la Miletrie, 86000 Poitiers, France. Electronic address: stephanie.ragot@univ-poitiers.fr. 19. Clinical Investigation Center CIC1402, CHU de Poitiers 2 rue de la Miletrie, 86000 Poitiers, France; CHU Poitiers, Diabetes Department, 2 rue de la Milétrie, CS 90577, 86000 Poitiers, France. Electronic address: samy.hadjadj@univ-nantes.fr. 20. L'institut du thorax, CHU Nantes, INSERM CIC1413, Hôpital Nord Laennec Boulevard Jacques-Monod Saint-Herblain, 44093 Nantes Cedex 1, France. Electronic address: bertrand.cariou@univ-nantes.fr. 21. Institut MITOVASC, UMR CNRS 6015, INSERM 1083, Université d'Angers, 3 rue Roger Amsler, 49100 Angers, France; Diabetes Department, CHU d'Angers, 4 rue Larrey, 49100 Angers, France. Electronic address: claire.briet@chu-angers.fr.
Abstract
AIM: To assess the relationship between sleep quality, fear of hypoglycemia, glycemic variability and psychological well-being in type 1 diabetes mellitus. METHODS: Our data were provided by the VARDIA Study, a multicentric cross-sectional study conducted between June and December 2015. Sleep characteristics were assessed by the Pittsburgh Sleep Quality Index (PSQI). Fear of hypoglycemia and psychological well-being were measured with the Hypoglycemia Fear Survey version II (HFS-II) and the Hospital Anxiety and Depression Scale (HADS), respectively. Glycemic variability (GV) was determined using the CV of three 7-point self-monitoring blood glucose profiles and the mean amplitude of glycemic excursion (MAGE). RESULTS: 315 patients were eligible for PSQI questionnaire analysis: 54% women, mean age 47 ± 15, mean diabetes duration of 24 ± 13 years, HbA1c of 7.6 ± 0.9% (60 ± 7,5mmol/mol). Average PSQI score was 6.0 ± 3.3 and 59.8% of the patients had a PSQI score > 5. HFS-II score and HADS were significantly higher among "poor" sleepers (p < 0.0001) and PSQI score was positively associated with HADS (β = 0.22; 95% CI = 0.08;0.35). GV evaluated by CV or MAGE did not differ between "poor" and "good" sleepers (p = 0.28 and 0.54, respectively). CONCLUSIONS: Adult patients with type 1 diabetes have sleep disturbances which correlate with psychological well-being. This study suggests that psychological management can be a target to improve sleep quality in adults with type 1 diabetes mellitus.
AIM: To assess the relationship between sleep quality, fear of hypoglycemia, glycemic variability and psychological well-being in type 1 diabetes mellitus. METHODS: Our data were provided by the VARDIA Study, a multicentric cross-sectional study conducted between June and December 2015. Sleep characteristics were assessed by the Pittsburgh Sleep Quality Index (PSQI). Fear of hypoglycemia and psychological well-being were measured with the Hypoglycemia Fear Survey version II (HFS-II) and the Hospital Anxiety and Depression Scale (HADS), respectively. Glycemic variability (GV) was determined using the CV of three 7-point self-monitoring blood glucose profiles and the mean amplitude of glycemic excursion (MAGE). RESULTS: 315 patients were eligible for PSQI questionnaire analysis: 54% women, mean age 47 ± 15, mean diabetes duration of 24 ± 13 years, HbA1c of 7.6 ± 0.9% (60 ± 7,5mmol/mol). Average PSQI score was 6.0 ± 3.3 and 59.8% of the patients had a PSQI score > 5. HFS-II score and HADS were significantly higher among "poor" sleepers (p < 0.0001) and PSQI score was positively associated with HADS (β = 0.22; 95% CI = 0.08;0.35). GV evaluated by CV or MAGE did not differ between "poor" and "good" sleepers (p = 0.28 and 0.54, respectively). CONCLUSIONS: Adult patients with type 1 diabetes have sleep disturbances which correlate with psychological well-being. This study suggests that psychological management can be a target to improve sleep quality in adults with type 1 diabetes mellitus.
Authors: Alessandro Bisio; Linda Gonder-Frederick; Ryan McFadden; Daniel Cherñavvsky; Mary Voelmle; Michael Pajewski; Pearl Yu; Heather Bonner; Sue A Brown Journal: J Diabetes Sci Technol Date: 2021-01-15
Authors: Kevin A Matlock; Melanie Broadley; Christel Hendrieckx; Mark Clowes; Anthea Sutton; Simon R Heller; Bastiaan E de Galan; Frans Pouwer; Jane Speight Journal: Diabet Med Date: 2021-10-07 Impact factor: 4.213